[{"id":"88f42f2b-3280-4f89-8f51-0e7028896643","acronym":"BELLWAVE-001","url":"https://clinicaltrials.gov/study/NCT03162536","created_at":"2021-01-18T15:35:37.913Z","updated_at":"2024-07-02T16:35:15.719Z","phase":"Phase 1/2","brief_title":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","source_id_and_acronym":"NCT03162536 - BELLWAVE-001","lead_sponsor":"ArQule, Inc., a subsidiary of Merck Sharp \u0026 Dohme LLC, a subsidiary of Merck \u0026 Co., Inc. (Rahway, NJ USA)","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BTK mutation • BCL6 translocation • BTK C481","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BTK mutation • BCL6 translocation • BTK C481"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nemtabrutinib (MK-1026)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 06/26/2017","start_date":" 06/26/2017","primary_txt":" Primary completion: 09/12/2025","primary_completion_date":" 09/12/2025","study_txt":" Completion: 09/12/2025","study_completion_date":" 09/12/2025","last_update_posted":"2024-03-08"}]